Project Grant K99HL175106
- This Project Grant award of $715,180 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to understand the epigenetic regulation of trained immunity in thoracic aortic aneurysms and dissections. The objective is to determine how monocytes/macrophages in the aortic wall are trained to exhibit a pro-inflammatory phenotype, with the goal of identifying key pathways driving this process. The research will be conducted by Baylor...
- The federal Project Grant award of $535,556.00 was provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Alabama at Birmingham (UAB). The funding will support a research project to investigate the role of a novel histone modification, H3T32 O-GlcNAc, in endothelial cell dysfunction and atherosclerosis. The 5-year project aims to elucidate the epigenetic features of this histone modification under...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to support research on modulating the resolution of angiogenesis and normalizing the vasculature for therapeutic benefit in cardiovascular diseases. The $549,665 award, effective January 15, 2025 through November 30, 2028, will fund research conducted by the University of Maryland, Baltimore to investigate mechanisms that regulate the resolution of angiogenesis,...
- This Project Grant award of $705,405 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to The Leland Stanford Junior University supports research focused on characterizing the role of adventitial fibroblasts in atherosclerosis. The research aims to identify new therapeutic targets and pathways related to this understudied cell population's influence on atherosclerotic plaque formation and calcification. The project will leverage single-cell genomics,...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $775,720 project grant to Yale University under the Cardiovascular Diseases Research federal grant program (CFDA 93.837) to conduct research on the role of endothelial protocadherins in vascular development and disease. The project aims to: 1) determine the effects of knocking out or inhibiting the protocadherin gamma (PCDHG) cluster in endothelial cells in mouse models of vascular inflammation, 2) elucidate the mechanism by which...
- This Project Grant award, valued at $167,400.00 and awarded by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research), will support research by Brigham & Women's Hospital Inc. to investigate how the immune mediator CD70 regulates endothelial metabolism and function, with the goal of identifying novel therapeutic targets for atherosclerotic cardiovascular disease. The 5-year project will comprehensively examine the role of CD70 in impairing endothelial...
- This Project Grant award, valued at $748,965.00, was provided by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to Northwestern University for a research project titled "Vascular Proliferative Resilience - Summary in Adults". The project aims to investigate the dynamics, spatial context, and molecular regulators of endothelial cell proliferation in the aorta, with the goal of deciphering the mechanisms underlying the maintenance of vascular...
- The University of Texas Southwestern Medical Center received a $772,275 Project Grant from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to conduct research on how endothelial cell scavenger receptor class B type I (SR-BI) is regulated and interacts with other proteins to drive LDL transcytosis and promote atherosclerosis. The award, effective August 25, 2025 through May 31, 2029, aims to determine the mechanisms by which hypercholesterolemia and...
- This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) totaling $706,220.00 supports research to elucidate the role of the nuclear pore protein NUP93 in regulating endothelial cell function and vascular health. The research aims to investigate how phosphorylation of NUP93 by the AKT signaling pathway impacts YAP localization and endothelial inflammation, as well as the in vivo importance of NUP93 phosphorylation in...
- This federal Project Grant award of $701,791 from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research to investigate the role of neddylation, a post-translational modification, in protecting endothelial cell integrity and function. The research aims to establish the pathophysiological significance of neddylation in the endothelium and identify key downstream effectors. The University of Nebraska, Lincoln is the awardee and will utilize...
This federal Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to Baylor College of Medicine provides $128,341 to investigate the role of endothelial cell nucleotide synthesis in atherosclerosis. The research aims to examine how disturbed blood flow induces endothelial DNA damage and the subsequent impact on the endothelial barrier, ultimately contributing to atherosclerotic lesion formation. Key objectives include elucidating the functions of the critical enzymes ATIC and CAD in regulating endothelial cell purine and pyrimidine synthesis, and evaluating their potential protective effects against atherosclerosis development. The award period runs from Sep 23, 2025 to Aug 31, 2027 and supports this foundational research to advance the understanding of cardiovascular disease mechanisms.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $128.3k | 9/23/25 |